Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD - a prospective interventional study
Language English Country Mexico Media print-electronic
Document type Clinical Trial, Journal Article
PubMed
39674369
DOI
10.1016/j.aohep.2024.101765
PII: S1665-2681(24)00548-9
Knihovny.cz E-resources
- Keywords
- Elastography, Intragastric balloon, Liver fibrosis, Non-alcoholic fatty liver disease, Obesity,
- MeSH
- Bariatric Surgery * MeSH
- Time Factors MeSH
- Equipment Design MeSH
- Adult MeSH
- Elasticity Imaging Techniques MeSH
- Weight Loss MeSH
- Liver Cirrhosis * etiology diagnostic imaging diagnosis MeSH
- Middle Aged MeSH
- Humans MeSH
- Non-alcoholic Fatty Liver Disease * diagnostic imaging diagnosis etiology MeSH
- Obesity * complications surgery diagnosis MeSH
- Pilot Projects MeSH
- Prospective Studies MeSH
- Treatment Outcome MeSH
- Gastric Balloon * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
INTRODUCTION AND OBJECTIVES: With increases in obesity and metabolic syndrome because of lifestyle-related factors, the prevalence of non-alcoholic fatty liver disease (NAFLD) also is increasing worldwide. In a subset of patients with NAFLD, an inflammatory process arises in the steatotic liver, known as non-alcoholic steatohepatitis, that leads to liver fibrosis and liver cirrhosis. In selected patients with obesity, bariatric surgery, and bariatric endoscopy are important therapeutic options. MATERIALS AND METHODS: This prospective interventional pilot study was conducted to investigate two types of intragastric balloons (IGB). The IGBs were the Orbera and the Spatz3. Liver fibrosis changes were monitored non-invasively using point and 2D shear wave ultrasound elastography (SWE) and transient elastography that allowed for quantification of liver steatosis using the controlled attenuation parameter (CAP). Patients were followed for 12 months. RESULTS: Of 34 patients implanted with an IGB, 30 completed follow-up at month 12; results for one patient were excluded because of initiation of obesity pharmacotherapy. Fifteen patients received the Orbera IGB, and nineteen patients received the Spatz3 type. In month 12, total and excess weight loss was 7.88 % and 30.13 %. Elastography values decreased from baseline (3.88 kPa) to 3.61 kPa at month 12 (p 0.024). 2D SWE values decreased from baseline (5.42 kPa) to a value of 4.91 kPa at month twelve (p 0.135). Transient elastography values decreased from baseline (5.62 kPa) to a value of 4.17 kPa at month twelve (p 0.009). CONCLUSIONS: Bariatric endoscopy in the form of IGB implantation leads to weight reduction and improvement of liver fibrosis and steatosis. GOV REGISTRATION: NCT04895943.
References provided by Crossref.org
ClinicalTrials.gov
NCT04895943
